MetaVia Inc. announced the completion of the final patient visit in its extended 24-week Phase 1 Part 3A clinical trial for DA-1726. The company previously reported positive interim results for the drug, including a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss. Full data from the study is expected in the first quarter of 2027, with a Phase 2 trial for MetALD and ALD planned for the second half of 2027.
MetaVia completes the last patient visit in the 24-week Phase 1 Part 3A study of DA-1726, having extended dosing from 16 to 24 weeks at 48 mg weekly. The release repeats hard interim figures: a statistically significant 68.1% placebo-adjusted liver fat reduction and 13.5% placebo-adjusted weight loss at Day 109. These are previously reported results, so today's news is largely a milestone rather than fresh data; the real catalysts are full Parts 3A/3B data in Q1 2027 and a Phase 2 start in H2 2027.
- ▲ Completion of final study visit in extended 24-week Phase 1 Part 3A on Nov. 17, 2026
- ▲ Full data from Parts 3A and 3B expected in Q1 2027
- ▼ The 68.1% and 13.5% efficacy figures are previously reported interim data, not new today
- ▼ Preliminary safety and tolerability observations are not the full dataset